SCHEMBL16402901

SCHEMBL16402901

CCN(c1cc(Cl)cc(C(=O)NCc2c(OC)nn(C)c2C)c1C)C1CCC(N(C)Cc2cccc(OCCOC)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 20/20 0.49
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16397419 1.00 EZH2 (0.49) EZH2CYP2D6CYP2C19
SCHEMBL16402763 0.87 EZH2 (0.51) EZH2
SCHEMBL16402685 0.87 EZH2 (0.51) EZH2
SCHEMBL16402546 0.87 EZH2 (0.51) EZH2
SCHEMBL16402501 0.87 EZH2 (0.51) EZH2
SCHEMBL16408169 0.87 EZH2 (0.52) EZH2CYP2D6CYP2C19
SCHEMBL16398235 0.87 EZH2 (0.52) EZH2CYP2D6CYP2C19
SCHEMBL16402311 0.87 EZH2 (0.52) EZH2CYP2D6CYP2C19
SCHEMBL16402370 0.86 EZH2 (0.48) EZH2
SCHEMBL16403118 0.86 EZH2 (0.48) EZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10150764-B2 Substituted benzene compounds Epizyme, Inc. (US) 2018-12-11 — — US disclosed
EP-3022184-B1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2017-09-27 — — EP disclosed
US-20160194316-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2016-07-07 — — US disclosed
EP-3022184-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2016-05-25 — — EP disclosed
WO-2015010049-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194316-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL EZH2 2519/4885CYP2D6 25/4885CYP2C19 140/4885
US-10150764-B2 Substituted benzene compounds CYP1B1, TP53, VHL EZH2 2519/4885CYP2D6 25/4885CYP2C19 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback